Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

R. Furman, Richard; P. Sharman, Jeff; Coutré, Steven; D. Cheson, Bruce; M. Pagel, John; Hillmen, Peter; C. Barrientos, Jacqueline; D. Zelenetz, Andrew; J. Kipps, Thomas; W. Flinn, Ian; Ghia, Paolo; Eradat, Herbert; J. Ervin, Thomas; Lamanna, Nicole; Coiffier, Bertrand; R. Pettitt, Andrew; Ma, Shuo; Stilgenbauer, Stephan; Cramer, Paula; Aiello, Maria; M. Johnson, Dave; L. Miller, Langdon; Li, Daniel; M. Jahn, Thomas; Dansey, Roger; Hallek, Michael; O’Brien, Susan

doi:10.1056/nejmoa1315226

Public

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

Published in New England Journal of Medicine • Jan 22, 2014

Authors:

Richard R. Furman

Jeff P. Sharman

Steven Coutré

Abstract

BACKGROUND: Patients with relapsed chronic lymphocytic leukemia (CLL) who have clinically significant coexisting medical conditions are less able to undergo standard chemotherapy. Effective therapies with acceptable side-effect profiles are needed for this patient population. METHODS: In this multic...

Subject

Medicine

Idelalisib

Chronic lymphocytic leukemia

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!